Pfizer recalls several batches of blood pressure medication containing carcinogens

Pfizer is not aware of any reports of adverse events associated with the recalled batches of drugs. This batch of Accupril was distributed in the US and Puerto Rico from December 2019 to April 2022.

Pfizer Canada also recalled lots of Accupril on April 21 after detecting the same impurity in the drug in excess of the legal limit.

Pfizer insists there is no immediate risk to patients taking the drugs in the recalled batches.

The substance found in the recalled Accupril is nitrosamine, which is common in water and food, but prolonged exposure above permissible levels can increase the risk. cancer.

Last month, Pfizer also recalled several batches of the blood pressure drug Accuretic and two authorized cheaper versions for possible carcinogenicity.

Last year, the drug company also recalled the smoking cessation drug Chantix due to high levels of nitrosamines in the drug.

Chantix was approved by US regulators in May 2006 as a prescription drug to help people 18 years of age and older quit smoking and is usually used for 12 to 24 weeks.